Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A211701||Alliance||A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort||Cancer Prevention and Control CIRB||Available to Open|
|A031201||Alliance||Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide; Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A071701||Alliance||Genomically-Guided Treatment Trial in Brain Metastases||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221504||Alliance||A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer||Cancer Prevention and Control CIRB||Available to Open|
|A011203||Alliance||A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic; Estrogen Receptor Positive; HER2 Negative Breast Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|A071702||Alliance||A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A171901||Alliance||Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice)||Cancer Prevention and Control CIRB||Available to Open|
|A081105||Alliance||Randomized Study of Erlotinib Vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091401||Alliance||Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031701||Alliance||A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations||Adult CIRB - Late Phase Emphasis||Available to Open|